Moleculin Biotech Inc
MBRX
NASDAQ
Biotechnology
$0.61
USD
+0.04 (+7.16%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $3.93M
Volume 1.5M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-39.97M
TTM
-48.1%
YoY
Operating Cash Flow
$-24.28M
TTM
-11.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.5 | 2.1 | 2.1 | 2.4 | 2.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 5.9 | 5.7 | 5.9 | 7.5 | 7.9 |
Operating Income | -5.9 | -5.7 | -5.9 | -7.5 | -7.9 |
EBITDA | -5.9 | -5.7 | -5.9 | -7.5 | -7.9 |
Other Income / Expense | 0.0 | -1.9 | -19.5 | 23.0 | -5.0 |
Total Other Income / Expense | 0.0 | -1.9 | -19.5 | 23.0 | -5.0 |
Income Before Income Taxes | -5.9 | -7.6 | -25.4 | 15.4 | -12.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -5.9 | -7.6 | -35.0 | 15.6 | -12.8 |
Consolidated Net Income / Loss | -5.9 | -7.6 | -25.4 | 15.4 | -12.8 |
Net Income Attributable to Common Shareholders | -5.9 | -7.6 | -25.4 | 15.4 | -14.6 |
Basic EPS | -$15.80 | -$12.25 | -$17.00 | $6.86 | -$3.54 |
Diluted EPS | -$15.80 | -$12.25 | -$17.00 | $6.86 | -$3.54 |
Basic Shares Outstanding | 0.4M | 0.6M | 1.5M | 2.3M | 4.1M |
Diluted Shares Outstanding | 0.4M | 0.6M | 1.5M | 2.3M | 4.1M |